Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | LPL | P06858 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008440 | 0.81 | HDAC2 (0.37) | HDAC2LPLLIPGALDH1A1HSD17B10 | |
| SCHEMBL7453950 | 0.74 | CSNK2A1 (0.40) | HDAC2LPLLIPGALDH1A1HSD17B10 | |
| SCHEMBL395258 | 0.73 | ALDH1A1 (0.54) | HDAC2ALDH1A1HSD17B10MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7453311 | 0.73 | CSNK2A1 (0.42) | HDAC2LPLLIPGALDH1A1HSD17B10 | |
| SCHEMBL8055265 | 0.71 | ESR1 (0.39) | ESR1LPLLIPGALDH1A1ADORA2A | |
| SCHEMBL15624627 | 0.71 | ALDH1A1 (0.42) | HDAC2ALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL19198893 | 0.71 | TDP1 (0.43) | HDAC2LPLLIPGALDH1A1HSD17B10 | |
| SCHEMBL3135893 | 0.69 | ALOX15 (0.65) | HDAC2LPLLIPGALDH1A1HSD17B10 | |
| SCHEMBL1016530 | 0.68 | ALDH1A1 (0.55) | HDAC2LPLLIPGALDH1A1HSD17B10 | |
| SCHEMBL6598923 | 0.68 | ESR1 (0.41) | ESR1LPLLIPGCSNK2A1PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12329741-B2 | HBV inhibitor and its use | XI'AN XINTONG PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2025-06-17 | — | — | US | disclosed |
| US-20240139152-A1 | HBV INHIBITOR AND ITS USE | XI'AN XINTONG PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2024-05-02 | — | — | US | disclosed |
| CN-117903110-A | HBV inhibitors and uses thereof | 西安新通药物研究股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11903924-B2 | HBV inhibitor and its use | XI'AN XINTONG PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2024-02-20 | — | — | US | disclosed |
| CN-114901639-B | HBV inhibitors and uses thereof | 西安新通药物研究股份有限公司 | 2023-11-24 | — | — | CN | disclosed |
| EP-3919474-B1 | HBV INHIBITOR AND USE THEREOF | XIAN XINTONG PHARMACEUTICAL RES CO LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| EP-4245372-A2 | HBV INHIBITOR AND USE THEREOF | Xi'An Xintong Pharmaceutical Research Co., Ltd. (CN) | 2023-09-20 | — | — | EP | disclosed |
| CN-114901639-A | HBV inhibitor and application thereof | 西安新通药物研究股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20220184035-A1 | HBV INHIBITOR AND ITS USE | XI'AN XINTONG PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2022-06-16 | — | — | US | disclosed |
| EP-3919474-A1 | HBV INHIBITOR AND USE THEREOF | Xi'An Xintong Pharmaceutical Research Co., Ltd. (CN) | 2021-12-08 | — | — | EP | disclosed |
| CN-101437827-A | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL IND LTD (JP) | 2009-05-20 | — | — | CN | disclosed |
| CN-101429200-A | Tricyclic benzopyran compound as anti-arrhythmic agents | NISSAN CHEMICAL IND LTD (JP) | 2009-05-13 | — | — | CN | disclosed |
| EP-2003135-A9 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-20090043100-A1 | Process for Producing Optically Active Chromene Oxide Compound | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-2003135-A2 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
| CN-1934116-A | Tricyclic benzopyran compounds useful as antiarrhythmic agents | NISSAN CHEMICAL IND LTD (JP) | 2007-03-21 | — | — | CN | disclosed |
| EP-1732929-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | Nissan Chemical Industries, Ltd. (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005090357-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-29 | — | — | WO | disclosed |
| US-3963717-A | ANTIINFLAMMATORY, ANALGESIC | SANDOZ, INC. (US) | 1976-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12329741-B2 | HBV inhibitor and its use | HAVCR2, HDGF, ZC3HAV1 | ESR1 1615/4885HDAC2 2033/4885LPL 4154/4885 |
| US-11903924-B2 | HBV inhibitor and its use | HAVCR2, HDGF, ZC3HAV1 | ESR1 1615/4885HDAC2 2033/4885LPL 4154/4885 |
| US-20240139152-A1 | HBV INHIBITOR AND ITS USE | HAVCR2, HDGF, ZC3HAV1 | ESR1 1615/4885HDAC2 2033/4885LPL 4154/4885 |
| US-20090043100-A1 | Process for Producing Optically Active Chromene Oxide Compound | CYP2C19, CYP2C9, CYP1A2 | ESR1 296/4885HDAC2 309/4885LPL 4305/4885 |
| US-20220184035-A1 | HBV INHIBITOR AND ITS USE | HAVCR2, HDGF, ZC3HAV1 | ESR1 1615/4885HDAC2 2033/4885LPL 4154/4885 |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | CBR1, CBR3, SCN8A | ESR1 1722/4885HDAC2 1100/4885LPL 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.